tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MAIA Biotechnology granted fast track designation for ateganosine

MAIA Biotechnology (MAIA) announced that the FDA has granted fast track designation for ateganosine for the treatment of non-small cell lung cancer. Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1